Askgene Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ask-gene.com
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 780
- Registration Number
- NCT06206733
- Locations
- 🇨🇳
Beijing cancer hospital, Beijing, China
A Study of ASKG712 in Patients With Diabetic Macular Edema
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05940428
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT05867420
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT05632939
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of ASKG315 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05554666
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Shanghai East Hospital, Shanghai, Shanghai, China
🇨🇳Shandong cancer hospital, Jinan, Shandong, China
A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05509985
- Locations
- 🇦🇺
The Alfred Hospital, Melbourne, Australia
🇦🇺Blacktown Hospital, Sydney, Australia
A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05456828
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath